Participated · Series A · Apr 2026

Siam Digital Lending operates an AI-first digital lending platform and has developed a proprietary agentic AI underwriting system called AiTHENA to assess credit and underwrite loans. The firm holds personal loan and nano loan licenses from the Bank of Thailand and offers mobile lending apps that have achieved over 300,000 organic downloads. Since launch, Thai customers have applied for more than 3 billion THB (~$100M) in funding through its platform. Management says AiTHENA analyzes thousands of factors to improve accuracy, speed, and cost-efficiency in lending and to expand financial inclusion. The company plans to deploy the Series A proceeds to accelerate expansion across Thailand and further scale its underwriting and product capabilities. SiamDL positions itself to capture part of Thailand's large personal-lending market, which it cites as roughly USD $20 billion annually.

Participated · Series A · Jul 2022

IQM Quantum Computers is a Finland-based developer of quantum computing technology. The company is preparing for public listings on Nasdaq and the Helsinki Stock Exchange. Ahead of those listings, IQM secured $146 million in PIPE financing tied to a SPAC combination with Real Asset Acquisition Corp., including a new commitment from Ilmarinen. IQM plans to use the funds to advance its technology and scale commercial operations. The financing strengthens the company’s near-term financial position as it moves toward becoming a public company.

Participated · Equity · Jan 2020

Temedica builds an ecosystem that combines health-related data from registries, sales, insurance, patient experience sources and, with explicit consent, patient-generated app data to produce actionable insights. The company processes more than 40 billion data points across over 50,000 diagnoses to derive insights on disease progression, treatment effectiveness, patient journeys, and medication adherence. Its insights are intended to serve patients, health care professionals, clinics, research institutions, pharma and biotech companies, and pharmacies. Led by CEO and founder Gloria Seibert, Temedica’s mission is to enable personalized and individualized medicine by focusing on patients and their individual needs. The company says it processes data in compliance with the GDPR. Temedica plans to use the new funding to accelerate expansion of its ecosystem and to advance its development efforts. Temedica builds a bundle of certified digital health apps for the German market, including Pelvina (pelvic‑floor training), Mineo (back training) and Waya (weight‑loss). Many of its apps are offered free to users through certifications and agreements with most German health insurers, and the company holds contracts with individual insurers. Public insurers had awaited confirmation from the central inspection agency that the apps are effective in preventive health. The startup intends to internationalise its products and will research differing regulatory frameworks across countries. The new funding is earmarked to scale the product suite and grow the team from about 40 employees to roughly 100 by year‑end.

Participated · Equity · Nov 2018

Movinga offers online booking for city-to-city house moves by combining logistics technology, a consumer app and a two-sided marketplace that works with professional relocation partners. The company currently operates in Germany, France and Sweden and employs almost 220 people. Movinga has expanded through acquisitions, including taking assets and staff from bankrupt competitor Move24, and says it acquired brands, IP, domains and technology from that business. The startup recently launched MovingaNow to enter inner-city local moves and plans real-time on-demand logistics under that brand with an algorithm-driven "Pool Service." It has leased electric Streetscooters for transports and plans a mix of professional companies and student helpers for MovingaNow initially. Planned expansion includes additional European countries (Austria and the Benelux region) and entry into international overseas moves. Movinga says it aims to reduce inefficiencies and under-utilised capacity in the fragmented relocation industry. Movinga is a European platform for house removals that aggregates removal jobs and dispatches work to partner removals companies. The company currently operates in Germany and France, focusing on intercity moves, and says it has facilitated over 30,000 moves since 2016. Movinga reports it is on track for annual revenues "significantly over 20 million Euros." The startup is investing in its technology to automate pricing and dispatch, and is building SaaS ERP tools to digitize processes for removals partners. It is exploring consumer add-on services such as switching electricity providers and arranging home broadband, and is targeting intracity and on-demand removals as future growth areas. The company says new capital will be used for further growth and to achieve operational break-even. Movinga is a Berlin-based removals marketplace that aimed to use technology to deliver instant algorithmically-generated quotes and help removal companies aggregate jobs. The company reportedly burned through much of its $25M Series B, saw two founders leave amid an unsubstantiated allegation of impropriety, and laid off a quarter of its staff. Now under new management, Movinga has raised €17M in a Series C and is positioning to recover. Management says the startup has spent months bolstering its development team and building out the platform to rely far less on manual work for quoting and job organisation. Product work includes a partner portal where removal companies can apply for single or pooled jobs and receive priority based on quality scores from customers. According to the company and investors, the tech has now caught up to its original narrative and investor participation is a vote of confidence in its ability to scale. Movinga is a Berlin-based online relocation startup that offers technology-enabled moving services by bundling professional partners and its own fleet of moving vans. The company claims it can relocate customers for up to 70% less than average moving firms by harnessing excess capacity and efficiently allocating resources. Movinga emphasizes strong customer service as a differentiator from traditional, mostly offline moving companies. It currently operates in Germany, Austria, Switzerland, France and the UK and plans to scale into Italy, the Benelux countries and Scandinavia. The startup is about a year old and has raised financing to support that expansion, including a recent $25 million round and an earlier €6 million funding round. Prior backers include Earlybird, Heilemann Ventures and various business angels such as Florian Heinemann and Philipp Kreibohm. Movinga is an online relocation company that sells and coordinates household moves using technology to bundle resources and manage logistics. The startup combines excess capacity from professional partners with its own fleet of moving vans to keep prices low. Movinga claims it can relocate customers for up to 70% less than average moving companies. The company emphasizes improved customer service compared with mostly offline incumbents. It currently operates in Germany, Austria, Switzerland, France and the UK. The latest investment is intended to help the company scale into Italy, Benelux and Scandinavia. Financially, Movinga has raised multiple rounds and its total funding has reached the "8 figures."

Led · Equity · Nov 2011

Affiris develops therapeutic peptide vaccines targeting chronic diseases. Its clinical pipeline includes three drug candidates for Parkinson’s disease, multiple system atrophy (MSA) and hypercholesterolemia, with additional preclinical candidates for diabetes, allergies, asthma and Huntington’s disease. The company initiated Phase 1 development of its hypercholesterolemia and atherosclerosis prevention candidates AT04A and AT06A, which target PCSK9, and expects data from that study in Q1 2017. The PCSK9-targeting approach aims to increase LDL receptors on the liver to reduce blood LDL cholesterol. Affiris has raised approximately €130m to date, roughly half of which comes from license income and government grants. The company employs 60 staff at the Campus Vienna Biocenter in Vienna, Austria. Leadership includes CEO Oliver Siegel and newly appointed CTO Günther Staffler. AFFiRiS AG is a Vienna-based developer of tailor-made peptide vaccines for Alzheimer’s disease, atherosclerosis, Parkinson’s disease, hypertension and several other conditions. The company’s current lead indication is Alzheimer’s disease. It intends to use the €25m in equity financing to advance its wide-ranging clinical development programme. Backers include Santo VC GmbH, which committed €20m, and existing investor MIG funds, which increased its stake by €5m via its MIG 11 fund. Both Santo VC and MIG hold options to extend their combined investment by a further €30m. Co-founded by CEO Walter Schmidt and CSO Frank Mattner, AFFiRiS employs 83 staff at the Campus Vienna Biocenter.